Associations - PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2
PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA E545	HER2 Positive Breast Cancer	PIK3CA E545	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
PIK3CA G1049R	HER2 Positive Breast Cancer	PIK3CA G1049R	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
PIK3CA H1047X	HER2 Negative Breast Cancer	PIK3CA H1047X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E545X	HER2 Negative Breast Cancer	PIK3CA E545X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PIK3CA E542K	HER2 Positive Breast Cancer	PIK3CA E542K	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PIK3CA K111N	Breast Cancer	PIK3CA K111N	Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
PIK3CA M1043I	HER2 Positive Breast Cancer	PIK3CA M1043I	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA H1047	HER2 Positive Breast Cancer	PIK3CA H1047	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PIK3CA Q546	HER2 Positive Breast Cancer	PIK3CA Q546	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

Associations(392)

Associations
(392)